News

Pfizer Inc. (NYSE:PFE) is among the 12 Best Ethical Companies to Invest in 2025. On July 24, 2025, Pfizer Inc. (NYSE:PFE) ...
As part of the agreement, which was signed in May 2025, 3SBio will receive $1.25bn, along with a $100m equity investment from ...
Pfizer agreed to an upfront payment of US$1.25 billion, US$150 million for mainland rights and a US$100 million equity ...
Moderna has scrapped plans to build an mRNA plant in Japan. Otsuka and Lundbeck's proposal for Rexulti as part of a PTSD ...
Northeastern Chinese company 3SBio to receive $1.25B, in addition to $100M equity investment, $150M for exclusive rights in ...
3SBIO and shareholder CITIC Private Equity are offering 606.1 million shares at an indicative price range of HK$8.30 to HK$9.10 each, putting the total deal at up to HK$5.51 billion, ...
SHANGHAI, Sept. 11, 2019 /PRNewswire/ -- According to Morgan Stanley Capital International's (MSCI) latest set of ESG ratings, 3SBio has been upgr ...
NuLeusin, 3SBio’s second generation IL-2 drug, would essentially be a new market for 3SBio (the company does have a legacy IL-2 product, but its sales are negligible).
3SBio is a leading biotech drugmaker in China. It is one of the earliest biologics innovators in the country, launching EPIAO in 1998 and TPIAO in 2005, which are market-leading innovative drugs ...
SHANGHAI, Sept. 11, 2019 /PRNewswire/ -- According to Morgan Stanley Capital International's (MSCI) latest set of ESG ratings, 3SBio has been upgraded to BBB status, surpassing that of 61% of ...